DDInter84 DDInter1376
Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976. During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Amphetamine {u} (Compound) resembles {v} (Compound) Monobenzone
Amphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Amphetamine {u} (Compound) binds {v} (Gene) CYP2D6
Amphetamine {u} (Compound) palliates {v} (Disease) narcolepsy
Amphetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Amphetamine {u} (Compound) causes {v} (Side Effect) Urinary tract infection
Amphetamine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Amphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Amphetamine (Compound) resembles Nateglinide (Compound)
Amphetamine (Compound) resembles Monobenzone (Compound)
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Amphetamine (Compound) binds CYP2D6 (Gene)
Amphetamine (Compound) palliates narcolepsy (Disease)
Amphetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Amphetamine (Compound) causes Urinary tract infection (Side Effect)
Amphetamine may lead to a major life threatening interaction when taken with Bupropion
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Amphetamine may lead to a major life threatening interaction when taken with Iobenguane